Related Experiment Video
Updated: Jun 23, 2026

Sexual Crosses with the Mucoromycete Phycomyces blakesleeanus
Published on: June 6, 2025
Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis
Susanna Naggie1, John R Perfect
1Division of Infectious Diseases, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA. naggi001@mc.duke.edu
Abstract:
Emerging fungi previously thought to be nonpathogenic are now recognized as playing a significant role in the increased incidence of invasive fungal disease. This change in the epidemiology of invasive fungal infections (IFIs) has occurred in the era of aggressive new therapies for hematopoietic stem cell transplantation and other malignancies that lead to profound immunosuppression for longer durations and has extended the survival of these critically ill patients. The significant morbidity and mortality associated with these infections is not only related to the host populations but to delayed recognition and diagnosis and high rates of resistance in some of these emerging pathogens to standard antifungal therapies.
Insights
Emerging fungi, once considered harmless, are increasingly causing invasive fungal diseases in immunocompromised patients. Delayed diagnosis and antifungal resistance complicate treatment and worsen outcomes for these critical infections.
Area of Science:
- Mycology
- Infectious Diseases
- Immunology
Background:
- Emerging fungal species previously deemed nonpathogenic are now implicated in a rise of invasive fungal diseases.
- This epidemiological shift coincides with advancements in immunosuppressive therapies for hematopoietic stem cell transplantation and malignancies.
- Extended survival of critically ill patients has increased their susceptibility to opportunistic infections.
Purpose of the Study:
- To highlight the changing landscape of invasive fungal infections (IFIs).
- To underscore the challenges posed by emerging fungal pathogens in immunocompromised populations.
- To emphasize the impact of delayed diagnosis and antifungal resistance on patient outcomes.
Main Methods:
- This study is a review of current epidemiological trends and clinical challenges.
- It synthesizes information on emerging fungal pathogens and their clinical significance.
- The analysis focuses on the interplay between host factors, therapeutic interventions, and pathogen characteristics.
Main Results:
- A significant increase in IFIs caused by previously nonpathogenic fungi has been observed.
- Profound and prolonged immunosuppression in patients undergoing intensive therapies contributes to higher infection rates.
- High rates of resistance to standard antifungal agents among emerging pathogens are a growing concern.
Conclusions:
- Emerging fungi represent a critical threat in immunocompromised patients, necessitating updated diagnostic and therapeutic strategies.
- The morbidity and mortality associated with IFIs are driven by host factors, diagnostic delays, and pathogen resistance.
- Effective management requires early recognition, accurate diagnosis, and tailored antifungal approaches to combat resistant strains.
Related Concept Videos
Fungal Group Zygomycota
Fungal Phylum Ascomycota
Fungal Phylum Basidiomycota
Overview of Fungi
Fungal Phylum Microsporidia
Cryptococcal Meningitis

